Cytocentric Visionaries: Randy Yerden, CEO BioSpherix
Part Three: Seeing Cytocentric Principles in Action
This post contains excerpts from an interview that Dr. Alicia Henn, Chief Scientific Officer of BioSpherix, conducted with Randy Yerden, Founder and CEO of BioSpherix.
In the 2nd part of this interview, we talked about the potentially reducing animal testing with relevant cell based assays by applying cytocentric principles. Today we talk about seeing Cytocentric Principles in action in research. Continue reading to learn how cytocentric principles have benefited research with cell based assays.
What have you found after all these years of working in this industry that is personally the most gratifying?
RY:It does kind of tickle me to read that a significant, positive result came from following a simple cytocentric principle. One of the most significant things in recent memory was this discovery by Hal Broxmeyer and his team when they extracted bone marrow stem cells and cord blood stem cells in physiologic oxygen. They found that this preserved the repopulating capability of these cells in transplants by a huge factor, just huge!
Who would have ever thought that?
With all the history of bone marrow transplants and the history of cord blood stem cell transplants, transplants that are so costly and that have become the standard of care? Who would have imagined that after all of these years, simply taking these cells out into room air had this devastatingly negative effect?
Who would have imagined that two of the cytocentric principles, being able to simulate physiologic conditions and full-time optimization of those conditions, would improve these valuable cells to such a great extent?
And the possibility of being able to take a cord blood stem cell sample, which may not have the number of cells needed for a full transplant, and make it enough stem cells for a transplant just by protecting the cells from room air?
That was one of those gee-whiz moments that sent me into heaven for days.
In the Part Four, we discuss helping make history with doctors who performed a first-of-its-kind surgery to implant a stem-cell seeded trachea into a toddler.
About the Author
Alicia D Henn, PhD, MBA
Alicia Henn has been the Chief Scientific Officer of BioSpherix, Ltd for two years. Previously, she was a researcher at the Center for Biodefense Immune Modeling in Rochester, NY. Alicia obtained her PhD in molecular pharmacology and cancer therapeutics from Roswell Park Cancer Institute in Buffalo, NY and her MBA from the Simon School at University of Rochester in Rochester, NY.